Oldest astronaut lands back on Earth on his 70th birthday
Nasa's oldest serving astronaut turned 70 as he hurtled back to Earth after a seven-month mission in space.
Don Pettit landed in Kazakhstan in the early hours of his milestone birthday, marking the end of his sixties and his mission aboard the International Space Station (ISS).
A Soyuz capsule carrying Mr Pettit, who is American, and two Russian cosmonauts landed on Sunday morning, hours after undocking from the ISS.
'Today at 0420 Moscow time (0120 GMT), the Soyuz MS-26 landing craft with Alexei Ovchinin, Ivan Vagner and Donald (Don) Pettit aboard landed near the Kazakh town of Zhezkazgan,' Russia's Roscosmos space agency said.
Space remains a rare avenue of cooperation between Russia and the US, whose relationship broke down after Vladimir Putin ordered the invasion of Ukraine in February 2022.
Mr Pettit and his crew mates, Mr Ovchinin and Mr Vagner, spent 220 days in space, orbiting the Earth 3,520 times and completing a journey of 93.3 million miles over the course of their mission.
It was Mr Pettit's fourth space flight, with the astronaut now having logged more than 18 months in orbit throughout his 29-year career.
Despite turning 70 as the mission ended, Mr Pettit is not the oldest person to fly in orbit. In 1998, the late John Glenn flew on a Nasa mission aged 77.
Images of the landing released by Nasa showed the small capsule parachuting down to Earth with the sunrise as a backdrop.
The trio landed in a remote area in Kazakhstan at 6:20am local time, after undocking from the space station just over three hours earlier.
One picture showed a frail-looking Mr Pettit giving a thumbs up as he was carried to a medical tent in his white space suit after landing back on Earth.
Nasa said Mr Pettit was 'doing well and in the range of what is expected for him following return to Earth'.
He is expected to travel to the Kazakh city of Karaganda and spend some time readjusting to gravity before boarding a Nasa plane to the agency's Johnson Space Center in Texas.
Meanwhile, Mr Ovchinin and Mr Vagner will go to Russia's space training base in Zvyozdniy Gorodok (Star City) near Moscow.
Mr Pettit spent his time on the ISS researching water sanitisation technology, 3D printing capabilities, plant growth in various conditions and fire behaviour in microgravity, Nasa said.
His time on the ISS largely overlapped with US astronauts Butch Wilmore and Suni Williams who were 'stranded' in space for nine months after the Boeing spacecraft they were testing suffered technical issues and was deemed unfit to fly them back to Earth.
The astronauts boarded a Boeing Starliner in June last year for what was meant to be an eight-day mission to the space station, but their return date was repeatedly pushed back after the shuttle's thrusters encountered problems.
They splashed down off the Gulf of Florida last month aboard a SpaceX Dragon capsule after spending 278 days on the ISS.
Their protracted stay became a political flashpoint, with Donald Trump and Elon Musk blaming former president Joe Biden for leaving them up there for political reasons.
Mr Wilmore and Ms Williams, whose initial eight-day mission was beset with delays, said last month they would return to space on the Boeing aircraft.
'We're going to rectify all the issues that we encountered. We're going to fix it, we're going to make it work', Mr Wilmore said.
'This is a tough business,' he added. 'The analogy about it's always a curvy road. It's never straight in this business.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Common menopause medication might prevent breast cancer while treating hot flashes
A drug intended to treat menopause symptoms could double as breast cancer prevention. New research from Northwestern University in Illinois found that Duavee, a Pfizer-made drug, "significantly reduced" breast tissue cell growth, which is a major indicator of cancer progression. A phase 2 clinical trial included 141 post-menopausal women who had been diagnosed with ductal carcinoma in situ (DCIS), also known as stage 0 breast cancer, according to a press release from Northwestern. Prostate Cancer Drug Now Available To More Patients With Aggressive Form Of Disease This non-invasive breast cancer affects more than 60,000 American women each year, often leading to an outcome of invasive breast cancer. The women were separated into two groups — one received Duavee and the other took a placebo for a month before undergoing breast surgery. Read On The Fox News App Duavee is a conjugated estrogen/bazedoxifene (CE/BZA) drug, which combines estrogen with another medication that minimizes the potential harmful side effects of the hormone. "The key takeaway from the study is that CE/BZA slows the growth (proliferation) of cells in milk ducts of DCIS that expressed the estrogen receptor significantly more than placebo," Dr. Swati Kulkarni, lead investigator and professor of breast surgery at Northwestern University Feinberg School of Medicine, told Fox News Digital. Experimental Women's Cancer Drug Boosts Survival Rates In Notable Study Another major finding is that the quality of life did not differ significantly between the two groups, but patients who took the CE/BZA reported fewer hot flashes during the study, she noted. "This would be expected, as the drug is FDA-approved to treat hot flashes." Kulkarni presented the study last week at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The findings are preliminary and have not yet been published in a medical journal. "What excites me most is that a medication designed to help women feel better during menopause may also reduce their risk of invasive breast cancer," said the doctor, who is also a Northwestern Medicine breast surgeon. Women who face a higher risk of breast cancer — including those who have experienced "high-risk lesions" — and who also have menopausal symptoms are most likely to benefit from the drug, according to Kulkarni. "These women are typically advised against standard hormone therapies, leaving them with few menopausal treatment options," the release stated. The researchers said they are "encouraged" by these early results, but more research is required before the medication can be considered for approval as a breast cancer prevention mechanism. "Our findings suggest that CE/BZA may prevent breast cancer, but larger studies with several years of follow-up are needed before we would know this for sure," Kulkarni told Fox News Digital. Dr. Sheheryar Kabraji, chief of breast medicine at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, was not involved in the study but commented on the findings. "While intriguing, this study is highly preliminary, and more research will be needed before we can conclude that conjugated estrogen/bazedoxifene (CD/BZA), a form of the hormone estrogen commonly prescribed to address symptoms of menopause, prevents invasive breast cancer or is effective at reducing cancer risk," she told Fox News Digital. Click Here To Sign Up For Our Health Newsletter Kabraji also noted that the study focused on reducing levels of one specific protein, "which does not always predict reduced recurrence of breast cancer." "This study did not directly show that CE/BZA treatment reduces the risk of DCIS recurrence or development of invasive cancer," she noted. "Importantly, however, patients who received this therapy experienced no worsening of quality of life, and saw improvement in vasomotor symptoms, such as hot flashes. If found to be effective in preventing breast cancer, CE/BZA is likely to have fewer side effects than current medications used for breast cancer prevention." For more Health articles, visit Lead researcher Kulkarni emphasized that this medication is not for the treatment of invasive breast cancer or DCIS. "Right now, we can say that women who are concerned about their risk of developing breast cancer can consider this medication to treat their menopausal symptoms," she article source: Common menopause medication might prevent breast cancer while treating hot flashes
Yahoo
8 minutes ago
- Yahoo
Trump's Threat to Kill SpaceX Presents One Hidden Safety Concern
Because of a political fallout, tech mogul and SpaceX owner Elon Musk has now attracted the verbal ire of President Trump. While sparring over social media, the President suggested that he could and would cancel Musk's government contracts relative to SpaceX. Briefly, this led Musk to claim that SpaceX would "decommission" the crucial Dragon spacecraft, but later reversed his position, saying, "Ok, we won't decommission Dragon." This is the very same type of vessel which recently led to the rescue of astronauts Butch Wilmore and Sunni Williams who were stranded on the International Space Station for much longer than originally planned. And it's the fate of the International Space Station that is actually the number one reason why an utterly defunded SpaceX might be a very dangerous thing. In 2024, NASA awarded SpaceX a contract valued at $843 million. The purpose? To deorbit the International Space Station by the end of the decade. Basically, the ISS is not designed to stay in orbit forever, and before it is replaced by something more permanent, it will have to be safely moved to a low Earth orbit. This means that SpaceX is currently tasked by the U.S. government to build the United States Deorbit Vehicle (USDV). "Selecting a U.S. Deorbit Vehicle for the International Space Station will help NASA and its international partners ensure a safe and responsible transition in low Earth orbit at the end of station operations," Ken Bowersox said in a NASA statement last a hypothetical world in which Trump decides to rescind all government contracts for SpaceX, that would presumably include killing the all-important job of SpaceX building the USDV. And if SpaceX doesn't build the USDV, who will help mitigate the very real fallout of a large space station? Again, hypothetically, there are other organizations that have spacecraft, but as the stranding of Wilmore and Williams recently demonstrated, SpaceX has proven to be the most reliable way for the U.S. to get people in and out of space. In fact, the whole reason that Wilmore and Williams were stranded was because the Boeing Starliner — a rival aerospace venture to SpaceX — was unable to complete a return trip because of safety concerns. Concurrent with all of this, Blue Origin's New Glenn craft isn't even close to being ready. Notably, Blue Origin's other craft, the New Shepard, isn't designed to go far enough into space to be useful to the ISS. One might wonder if SpaceX really needs the money. And it's possible the company doesn't. As Musk pointed out on June 3, the entirety of what NASA pays to SpaceX ($1.1 billion) is dwarfed by SpaceX's current revenue ($15.5 billion). Basically, SpaceX's Starlink services are making plenty of money for the company, so if Trump rescinded even just that contract valued at roughly $800 million, it wouldn't come close to putting SpaceX out of business. Legally, Trump might be able to try and sever ties between SpaceX and the U.S. government, specifically, NASA. But practically speaking, this seems very unlikely long-term. Right now, SpaceX is the best bet for creating a safe deorbit for the ISS. And, if any more astronauts get stranded — from any country — it seems like Musk's Dragons are still the most reliable space Threat to Kill SpaceX Presents One Hidden Safety Concern first appeared on Men's Journal on Jun 6, 2025
Skift
25 minutes ago
- Skift
NASA Faces Steep Budget Cuts, One Space Meeting Has Already Been Scrapped
The White House has proposed the largest single-year budget cut to NASA in U.S. history. As a result, space science and exploration are taking a hit — and so are the cornerstone conferences that support these efforts. NASA is facing a proposed 24% budget cut. The financial uncertainty is already hitting the events sector. The International Space Station Research and Development Conference, planned for July in Seattle, has been canceled just two months out. 'The International Space Station National Laboratory, in close consultation with NASA, has determined that the current regulatory and budgetary environment does not support holding the International Space Station Research and Development Conference in 2025,' said the Center for the Advancement of Science in Space. The event, held annually for over a decade, spotlighted research aboard the station and offered updates on NASA's work. NASA Puts Lunar and Planetary Science Conference at Risk The uncertainty doesn't end there. NASA has announced it will no longer fund or seek partners for the 2026 Lunar and Planetary Science Conference, a fixture of the planetary science calendar. NASA still send staff and participate but expects outside organizations to cover all costs. The conference organizer says it intends to host the 57th event next year. Some doubt that will happen. 'The lead time it takes to find a venue, speakers, sponsors, and all that goes into it may prohibit a 2026 gathering from happening,' said Paul Byrne, a planetary scientist at Washington University in St. Louis, who hasn't missed a Lunar and Planetary Science Conference since first attending as a graduate student in 2007. 'This meeting is vital. It's the lifeblood of our community. Plus, it's an extremely important resource for early career scientists,' Byrne said.'This is the go-to meeting, and if it goes away it is an indicator of the crises we are facing.' These cancellations follow a broader trend. NASA's Science Mission Directorate has steadily pulled back support for community-led meetings and workshops.
